UNSPSC 51334104: Lurasidone hydrochloride

This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0P4I5851I. European Medicines Agency schedules Lurasidone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34204. Lurasidone hydrochloride generally arises in the molecular formula C28H36N4O2S.CLH. The term 'lurasidone hydrochloride' is a United States Adopted Name designation.

UNSPSC 51334104 Lurasidone hydrochloride is a Commodity code for a prescription antipsychotic medication, but recent state and local procurement activity under this code does not reflect solicitations for lurasidone specifically. Instead, the posted opportunities tagged to this code cover broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local issuers pursuing pharmaceutical supply include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon participants). Work under this code in practice spans emergency medication distribution, pharmacy benefit optimization, and bulk generic drug sourcing through authorized wholesale channels rather than procurement of any single branded or generic pharmaceutical product.

Geographic activity appears concentrated in the Southeast and Midwest, with documented recent opportunities in Florida, Texas, and Minnesota–Oregon. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, supported through what may be FEMA funding and requiring fixed-fee pricing, workers' compensation and commercial general liability insurance, and E-Verify compliance. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013, April 3, 2026) to assess vendor capability for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, requiring current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, $5 million commercial general liability and $2 million network security and professional liability coverage, and a 3 percent administrative fee on all purchases. The mismatch between the nominal code (a single branded antipsychotic) and the actual procurement scope suggests this code may be used inconsistently by state and local buyers, or that lurasidone is bundled into broader pharmaceutical aggregate contracts.